The Sunday Roast featuring James Short, CEO of Celadon Pharmaceuticals (AIM:CEL) & Charles Bray, Chairman of Aterian (LSE:ATN) #GGP #BSFA #CHLL #VDTK #ATN #PRD #CEL
Season 5, Episode 35, Mar 19, 2023, 11:45 AM
Phil Carroll and Kevin Hornsby talk to Jim regarding his background and the recent home office license upgrade which will enable Celadon to commence the commercial supply of its GMP pharmaceutical cannabis product. GMP registration is understood to be the first such registration of a UK pharmaceutical facility for high THC cannabis active pharmaceutical ingredients since the legalisation of medical cannabis in 2018.
Charles joins the podcast to talk about trading tantalum in Rwanda and how the various processes work.
As usual, there is a weekly round-up of the movers and shakers and a look at the biggest news stories of the past week.
Disclaimer & Declaration of Interest
The information, investment views, and recommendations in this podcast are provided for general information purposes only. Nothing in this podcast should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the commentator but no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion
Charles joins the podcast to talk about trading tantalum in Rwanda and how the various processes work.
As usual, there is a weekly round-up of the movers and shakers and a look at the biggest news stories of the past week.
Disclaimer & Declaration of Interest
The information, investment views, and recommendations in this podcast are provided for general information purposes only. Nothing in this podcast should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the commentator but no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion